Previous 10 | Next 10 |
2023-11-14 10:00:40 ET DENVER, Colo., Nov. 14, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; BioCardia Inc (NASDAQ: BCDA), INVO Bioscience Inc (NASDAQ: INVO), Theseus Pharmaceuticals Inc (NASDAQ: THRX),...
2023-11-14 07:53:50 ET More on BioCardia BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript BioCardia doesn't see Phase 3 study meeting primary endpoint, stock slides Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia...
2023-11-14 07:47:47 ET DENVER, Colo., Nov 14, 2023 ( www.247marketnews.com )- BioCardia Inc (NASDAQ: BCDA) stated, this morning, that the Food and Drug Administration (FDA) approved its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with i...
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical tria...
2023-11-08 20:08:03 ET BioCardia, Inc. (BCDA) Q3 2023 Earnings Conference Call November 08, 2023, 04:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and Chief Executive Officer David McClung - Chief Financial Officer ...
2023-11-08 16:51:53 ET More on BioCardia BioCardia doesn't see Phase 3 study meeting primary endpoint, stock slides Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Financial information for BioCardia For further...
SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2023 and filed its quarterly report o...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
BioCardia Inc. (BCDA) is expected to report $-0.12 for Q3 2023
SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for t...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therap...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...